07:00 , Mar 21, 2011 |  BC Week In Review  |  Company News

Maxygen, Astellas deal

Astellas exercised its option to acquire Maxygen's 83.3% stake in the companies' JV Perseid Therapeutics LLC for $76 million in cash. In 2009, the partners formed the JV, into which Maxygen transferred substantially all of...
08:00 , Feb 7, 2011 |  BC Week In Review  |  Clinical News

ASP2408: Phase I started

The companies' Perseid Therapeutics LLC JV began a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial to evaluate single ascending-doses of IV ASP2408 in 65 healthy volunteers. The trial start triggered a $10 million payment to...